Matinas Biopharma Holdings Inc

ASE:MTNB   3:56:19 PM EDT
0.81
-0.03 (-3.69%)
Products, Strategic Combinations

Matinas Biopharma Announces Collaboration With National Institute Of Allergy And Infectious Diseases To Evaluate Oral Formulations Of Gilead’s Antiviral Remdesivir Utilizing Matinas’ LNC Platfor

Published: 12/07/2020 11:50 GMT
Matinas Biopharma Holdings Inc (MTNB) - Matinas Biopharma Announces Collaboration With the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas’ Lnc Platform Delivery Technology.
Matinas Biopharma - Any Product Generated As a Part of Efforts by Matinas and Niaid Would Require a License From Gilead for Use of Remdesivir.
Matinas Biopharma - Any Product Generated As a Part of Efforts by Matinas and Niaid Would Require License From Matinas for Use of Lnc Formulation.